CT测量的体积强化肿瘤负荷预测神经内分泌肝转移患者经动脉内治疗后的生存结局
本回顾性研究纳入119例接受动脉内治疗的多灶性神经内分泌肝转移患者,评估对比增强CT测量的肝脏强化肿瘤负荷(LETB)能否预测早期反应和生存结局。结果显示LETB变化可预测总生存、不可再次动脉内治疗进展时间、肝脏及全身无进展生存,且判别能力优于RECIST和mRECIST。
要点
- LETB变化是神经内分泌肝转移动脉内治疗后生存的独立预测因素。
- RECIST和mRECIST均未能预测患者结局。
- LETB较RECIST/mRECIST能更好判别生存结局。
核心结论
- 根据LETB变化判定的缓解有助于预测神经内分泌肝转移患者动脉内治疗后的生存结局,判别能力优于RECIST和mRECIST。
研究设计与样本
- 回顾性研究纳入119例(平均年龄60岁±11[SD],61例男性)多灶性神经内分泌肝转移患者,2006年4月至2018年12月间接受161次动脉内治疗(栓塞TAE或化疗栓塞TACE),以RECIST和mRECIST评估肿瘤反应,LETB定义为衰减值高于非肿瘤肝实质感兴趣区2个标准差以上的区域。
关键影像表现/征象
- LETB变化中位数-25.8%最佳判别总生存(缓解者83个月 vs 非缓解者51个月,P=0.02)。
- LETB变化中位数-25.8%最佳判别全身无进展生存(缓解者18个月 vs 非缓解者8个月,P<0.001)。
- LETB变化-10%最佳判别不可再次动脉内治疗进展时间(缓解者32个月 vs 非缓解者12个月,P<0.001)。
- LETB变化-10%最佳判别肝脏无进展生存(缓解者18个月 vs 非缓解者8个月,P<0.001)。
诊断标准与关键数值
- LETB测量为衰减值高于非肿瘤肝实质感兴趣区2个标准差以上的区域。
- LETB变化中位数-25.8%最佳判别总生存和全身无进展生存。
- LETB变化-10%最佳判别不可再次动脉内治疗进展时间和肝脏无进展生存。
临床应用与阅片要点
- 多变量分析显示LETB变化独立关联总生存改善(HR 0.56)。
- 多变量分析显示LETB变化独立关联不可再次动脉内治疗进展时间改善(HR 0.44)。
- 多变量分析显示LETB变化独立关联肝脏无进展生存改善(HR 0.42)。
- 多变量分析显示LETB变化独立关联全身无进展生存改善(HR 0.47)。
- RECIST和mRECIST均未能预测患者结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To investigate whether liver enhancing tumor burden (LETB) assessed at contrast-enhanced CT indicates early response and helps predict survival outcomes in patients with multifocal neuroendocrine liver metastases (NELM) after intra-arterial treatment. Materials and Methods This retrospective study included patients with NELM who underwent intra-arterial treatment with transarterial embolization (TAE) or chemoembolization (TACE) between April 2006 and December 2018. Tumor response in treated NELM was evaluated by using the Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST). LETB was measured as attenuation 2 SDs greater than that of a region of interest in the nontumoral liver parenchyma. Overall survival (OS); time to unTA(C)Eable progression, defined as the time from the initial treatment until the time when intra-arterial treatments were considered technically unfeasible, either not recommended by the multidisciplinary tumor board or until death; and hepatic and whole-body progression-free survival (PFS) were evaluated using multivariable Cox proportional hazards analyses, the Kaplan-Meier method, and log-rank test. Results The study included 119 patients (mean age, 60 years ± 11 [SD]; 61 men) who underwent 161 treatments. A median LETB change of -25.8% best discriminated OS (83 months in responders vs 51 months in nonresponders; P = .02) and whole-body PFS (18 vs 8 months, respectively; P < .001). A -10% LETB change best discriminated time to unTA(C)Eable progression (32 months in responders vs 12 months in nonresponders; P < .001) and hepatic PFS (18 vs 8 months, respectively; P < .001). LETB change remained independently associated with improved OS (hazard ratio [HR], 0.56), time to unTA(C)Eable progression (HR, 0.44), hepatic PFS (HR, 0.42), and whole-body PFS (HR, 0.47) on multivariable analysis. Neither RECIST nor mRECIST helped predict patient outcome. Conclusion Response according to LETB change helped predict survival outcomes in patients with NELM after intra-arterial treatments, with better discrimination than RECIST and mRECIST. Keywords: CT, Chemoembolization, Embolization, Abdomen/GI, Liver Supplemental material is available for this article. © RSNA, 2023.
引用
- Assouline J, Cannella R, Porrello G, et al. Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment. Radiol Imaging Cancer. 2023. PMID: 36607243. doi:10.1148/rycan.220051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。